Results 211 to 220 of about 106,290 (280)

Impact of Physical Frailty on Early Intolerance to CAPOX Chemotherapy in Patients With Colon, Rectal, and Gastric Cancer

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Patients with gastrointestinal cancer often present reduction in functional capacity and develop frailty, which increases the risk of chemotherapy intolerance. We investigated whether physical frailty is associated with early intolerance to CAPOX (capecitabine+oxaliplatin) in patients with colon, rectal, or gastric cancer.
Isabella Pellegrini Grama Pereira Lima, Nicolle Martins Carrozzi, Talita Oliveira Silva, Karina Almeida de Brunheroti, Joyce Lucchesi, Andréia Cristina Dalbello Rissati, Lucinea Valério de Almeida Castro, Maria Carolina Santos Mendes, José Barreto Campello Carvalheira, Lígia M. Antunes‐Correa   +9 more
wiley   +1 more source

Absolute Bioavailability of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC): Systemic Pharmacokinetics of the CRC-PIPAC-II Trial. [PDF]

Ann Surg Oncol
van den Heuvel TBM, Rauwerdink P, Hulshof E, van de Vlasakker VCJ, Moes DJAR, Pluimakers G, Rovers KPB, Creemers GJ, Burger PJWA, Nienhuijs SW, Wiezer RJ, Lurvink RJ, Boerma D, De Hingh IHJT, Deenen MJ.   +14 more
europepmc   +1 more source

Simultaneous Establishment of Autologous Colorectal Cancer and Mesothelial Stromal Cell Lines from Malignant Ascites Reveals a Mesothelial‐Stromal FGFR3 Axis as a Potential Vulnerability in Peritoneal Metastasis

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Colorectal cancer (CRC) with peritoneal dissemination remains a major therapeutic challenge because of poor prognosis and limited treatment options. Experimental models that accurately recapitulate tumor–mesothelial interactions are scarce. Here, we report the establishment of a novel autologous paired model comprising a CRC cell line (OMUCR‐1)
Yasuhiro Fukui, Hiroaki Kasashima, Zizhou Wang, Iguru Omori, Yukina Kusunoki, Kanae Echizen, Yoshiki Nonaka, Yuki Seki, Kenji Kuroda, Yuichiro Miki, Mami Yoshii, Tatsunari Fukuoka, Tatsuro Tamura, Masatsune Shibutani, Takahiro Toyokawa, Yu Muta, Yuki Nakanishi, Masakazu Yashiro, Naoko Ohtani, Kiyoshi Maeda   +19 more
wiley   +1 more source

Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial-the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial. [PDF]

BMJ Open
Shimomura M, Ishikawa S, Miguchi M, Shinozaki K, Ikeda S, Kobayashi H, Nakahara M, Sumitani D, Shimizu W, Kohyama M, Saito Y, Mukai S, Hirata Y, Kochi M, Shimizu Y, Takakura Y, Yoshimitsu M, Kodama S, Uegami S, Yano T, Okuda H, Ohdan H, Hiroshima Surgical study group of Clinical Oncology (HiSCO).   +22 more
europepmc   +1 more source

Predicting Prognosis for Gastric Cancer Patients Receiving Neoadjuvant Treatment With Body Composition‐Based Deep Learning

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background This study sought to develop an innovative body composition (BC)‐based deep learning (DL) model to precisely evaluate survival in gastric cancer (GC) patients undergoing neoadjuvant treatment (NT). Materials and Methods This retrospective study included GC patients undergoing NT from two centers.
Yingjing Zhang, Tong Tong, Bowen Hou, Tian Yu, Pengfei Su, Jianchun Yu, Yakai Huang   +6 more
wiley   +1 more source

Usefulness of pharmacy outpatient clinic follow-up for maintaining relative dose intensity in patients on adjuvant CAPOX chemotherapy for gastric cancer. [PDF]

Mol Clin Oncol
Nakamura M, Yokokawa T, Kawakami K, Kimura Y, Shimizu H, Kobayashi K, Aoyama T, Suzuki W, Hatori M, Suzuki K, Takahari D, Ogura M, Chin K, Wakatsuki T, Yamaguchi K, Yamaguchi M.   +15 more
europepmc   +1 more source

Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT The efficacy of PD‐1 inhibitor pucotenlimab (HX008) in solid tumors exhibits heterogeneity. This study integrated data from 6 clinical trials (covering gastric/gastroesophageal junction cancer, triple‐negative breast cancer, melanoma, and dMMR/MSI‐H solid tumors) using Bayesian meta‐analysis, machine learning (optimal XGBoost AUC = 0.86), and ...
Yingge He, Changqing Gao, Shiyan Zhang, Yonghui Hao, Shuning He, Ke Peng, Liqi Li   +6 more
wiley   +1 more source

Safety and feasibility of total neoadjuvant FLOT chemotherapy in locally-advanced gastric and gastroesophageal junction cancer. [PDF]

Oncol Lett
Dobrzhanskyi O, Horodetskyi A, Pepenin M, Kondratskyi Y.   +3 more
europepmc   +1 more source

Efficacy of Hepatic Artery Infusion Chemotherapy Combined With Regorafenib and Sintilimab Versus Regorafenib Alone in MSS/pMMR Colorectal Cancer Liver Metastases After Second‐Line Treatment Failure

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer liver metastases (CRCLM) have limited treatment options after failure of second‐line systemic therapies. Hepatic artery infusion chemotherapy (HAIC) combined with targeted therapy and immunotherapy may offer improved outcomes.
Ran You, Qingyu Xu, Lixing Wang, Bin Leng, Chendong Wang, Zeyu Yu, Ya Lu, Lingfeng Diao, Yi Lu, Guowen Yin   +9 more
wiley   +1 more source

Patient-derived organoids predict chemotherapy response of locally advanced gastric cancer. [PDF]

PLoS One
Huang M, Chu J, Yu W, Dou L, Wang Q, Jiang F, Wei M, Cui X, Zhao W, Zhou J, Li S, Liu L.   +11 more
europepmc   +1 more source